Merck KGaA MS Pill Rejected by European Drug Agency

European regulators rejected Merck KGaA’s multiple sclerosis pill cladribine, the second setback this week for the German drugmaker in the race with Novartis AG for a share of a new market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.